Dr Lamont Zebediah Barnett, PHD, LCAS-A, MAC | |
2747 Sunset Ave Ste 109, Rocky Mount, NC 27804-3751 | |
(919) 539-9400 | |
Not Available |
Full Name | Dr Lamont Zebediah Barnett |
---|---|
Gender | Male |
Speciality | Counselor - Addiction (substance Use Disorder) |
Location | 2747 Sunset Ave Ste 109, Rocky Mount, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902327109 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Lamont Zebediah Barnett, PHD, LCAS-A, MAC 2011 Princeton Town St, Knightdale, NC 27545-9635 Ph: (919) 539-9400 | Dr Lamont Zebediah Barnett, PHD, LCAS-A, MAC 2747 Sunset Ave Ste 109, Rocky Mount, NC 27804-3751 Ph: (919) 539-9400 |
News Archive
From 1995 to 2006, hospital 30-day death rates decreased significantly for Medicare patients hospitalized for a heart attack, as did the variation in the rate between hospitals, according to a study in the August 19 issue of JAMA.
In a study that included more than 800 women who had undergone surgery for breast cancer, the majority reported some level of pain 12 months after surgery, and factors associated with pain included chronic preoperative pain, chemotherapy, preoperative depression and pain in the area to be operated, according to a study appearing in the January 1 issue of JAMA.
The FDA announced that Avastin, while still approved for other cancers, is more harmful than helpful to breast cancer patients.
Scientists have discovered new evidence about the evolution of viruses, in work that will change our understanding about the control of infectious diseases such as winter flu.
Covidien, a leading global provider of healthcare products and recognized innovator in intermittent pneumatic compression (IPC), today announced 510(k) clearance from the U.S. Food and Drug Administration for the Kendall SCD™ Sequential Compression Comfort Sleeve and Kendall SCD™ 700 Series Controller. The new system will be launched next month in the U.S. and will deliver an improved level of comfort for patients, while reducing the risk of venous thromboembolism (VTE).
› Verified 8 days ago